Journal of Neuro-Oncology

, Volume 110, Issue 2, pp 237–243 | Cite as

Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas

  • Sean A. Grimm
  • Maryanne Marymont
  • James P. Chandler
  • Kenji Muro
  • Steven B. Newman
  • Robert M. Levy
  • Borko Jovanovic
  • Katie McCarthy
  • Jeffrey J. Raizer
Clinical Study


To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas. A 3 + 3 dose escalation study was performed in patients with newly diagnosed glioblastoma, anaplastic astrocytoma (AA), and anaplastic oligoastrocytoma (AOA). All patients received RT 59–61 Gy in 28–33 fractions, TMZ for 42 days, and ATO 1–2 h prior to RT for 5 days during the first week, then twice weekly until completing RT. Dose levels (DL) were: (1) TMZ 60 mg/m2/ATO 0.2 mg/kg; (2) TMZ 75 mg/m2/ATO 0.2 mg/kg; (3) TMZ 75 mg/m2/ATO 0.25 mg/kg. Dose-limiting toxicity (DLT) was defined as grade 3 non-hematologic toxicity or grade 4 toxicity of any type from enrollment until 3 weeks after finishing RT. 17 patients (13 glioblastoma, 4 AA/AOA) were accrued. Median age was 52 (range 25–80). Median KPS was 90 %. DLT’s occurred at DL 2 (grade 4 transaminase elevation) and DL 3 (grade 4 neutropenia and grade 3 QTc prolongation). The MTD of TMZ 75 mg/m2/ATO 0.2 mg/kg was safe and well tolerated. A phase II study evaluating the efficacy of this combination is underway.


Glioblastoma Malignant glioma Chemoradiation Arsenic trioxide Central nervous system tumor 


  1. 1.
    CBTUS (2005) Statistical report: primary brain tumors in the United States, 1998–2002. Published by the Central Brain Tumor Registry of the United StatesGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  3. 3.
    Brem SS, Bierman PJ, Brem H et al (2011) Central nervous system cancers. J Natl Compr Cancer Netw 9(4):352–400Google Scholar
  4. 4.
    Cairncross JG, Wang M, Shaw EG, et al (2012) Chemotherapy plus radiotherapy versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. J Clin Oncol (suppl; abstr 2008b)Google Scholar
  5. 5.
    van den Bent MJ, Hoang-Xuan K, Brandes AA, et al (2012) Long-term follow-up results of EORTC 26951: a randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol (suppl: abstr 2)Google Scholar
  6. 6.
    Miller WH Jr, Schipper HM, Lee JS et al (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893–3903PubMedGoogle Scholar
  7. 7.
    Kim JH, Lew YS, Kolozsvary A et al (2003) Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 160:662–666PubMedCrossRefGoogle Scholar
  8. 8.
    Lew YS, Kolozsvary A, Brown SL et al (2002) Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 62:4202–4205PubMedGoogle Scholar
  9. 9.
    Ning S, Knox SJ (2004) Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys 60:197–203PubMedCrossRefGoogle Scholar
  10. 10.
    Ning S, Knox SJ (2006) Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys 65:493–498PubMedCrossRefGoogle Scholar
  11. 11.
    Zhen Y, Zhao S, Li Q et al (2010) Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett 292:64–72PubMedCrossRefGoogle Scholar
  12. 12.
    Fatoo A, Nanaszko MJ, Allen BB et al (2011) Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol 103:397–408PubMedCrossRefGoogle Scholar
  13. 13.
    Lim SK, Llaguno SR, McKay RM et al (2011) Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep 44:158–164PubMedCrossRefGoogle Scholar
  14. 14.
    List A, Beran M, DiPersio J et al (2003) Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukeumia 17:1499–1507CrossRefGoogle Scholar
  15. 15.
    Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  16. 16.
    Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2:187–193PubMedGoogle Scholar
  17. 17.
    Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410PubMedCrossRefGoogle Scholar
  18. 18.
    Knipp S, Gattermann N, Schapira M et al (2007) Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 31:1585–1587PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Sean A. Grimm
    • 1
  • Maryanne Marymont
    • 2
  • James P. Chandler
    • 3
  • Kenji Muro
    • 3
  • Steven B. Newman
    • 4
  • Robert M. Levy
    • 3
  • Borko Jovanovic
    • 5
  • Katie McCarthy
    • 6
  • Jeffrey J. Raizer
    • 6
  1. 1.Department of NeurologyFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  2. 2.Department of Radiation OncologyFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  3. 3.Department of NeurosurgeryFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  4. 4.Department of MedicineFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  5. 5.Department of Preventative MedicineFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  6. 6.Department of NeurologyFeinberg School of Medicine, Northwestern UniversityChicagoUSA

Personalised recommendations